PL320922A1 - Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes - Google Patents

Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes

Info

Publication number
PL320922A1
PL320922A1 PL95320922A PL32092295A PL320922A1 PL 320922 A1 PL320922 A1 PL 320922A1 PL 95320922 A PL95320922 A PL 95320922A PL 32092295 A PL32092295 A PL 32092295A PL 320922 A1 PL320922 A1 PL 320922A1
Authority
PL
Poland
Prior art keywords
somulating
mhc
molecules
prevention
bonding
Prior art date
Application number
PL95320922A
Inventor
Roger Pascal Lauener
Original Assignee
Om Lab Sa
Deutsche Om Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Lab Sa, Deutsche Om Arzneimittel Gmbh filed Critical Om Lab Sa
Publication of PL320922A1 publication Critical patent/PL320922A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
PL95320922A 1994-12-23 1995-12-27 Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes PL320922A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
PCT/EP1995/005164 WO1996020215A2 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
PL320922A1 true PL320922A1 (en) 1997-11-10

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95320922A PL320922A1 (en) 1994-12-23 1995-12-27 Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes

Country Status (11)

Country Link
EP (1) EP0800534A2 (en)
JP (1) JPH10511652A (en)
CN (1) CN1171117A (en)
AU (1) AU4347696A (en)
BR (1) BR9510554A (en)
CA (1) CA2208233A1 (en)
CZ (1) CZ186897A3 (en)
HU (1) HUT77468A (en)
PL (1) PL320922A1 (en)
SK (1) SK80697A3 (en)
WO (1) WO1996020215A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
EP0889964A1 (en) 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
AU2002317285B2 (en) * 2001-07-02 2007-05-24 Aimsco Limited Use of polyclonal anti-HIV goat serum as a therapeutic agent
JP2005532261A (en) * 2002-01-28 2005-10-27 エイムスコ・リミテッド Treatment
ES2232273B1 (en) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos NEW THERAPEUTIC APPLICATIONS OF GLUCOPROTEIN CD14S.
CN1787741B (en) * 2003-05-15 2011-08-17 唐纳士公司 Methods and compositions for the prevention and treatment of sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
GB8310403D0 (en) * 1983-04-18 1983-05-25 Mach B F Cotransformed mouse cells
JPS6225994A (en) * 1985-05-30 1987-02-03 ジエネテイツク　システムズ　コ−ポレイシヨン Monoclonal antibody for separating hla type
JPS63275526A (en) * 1987-05-03 1988-11-14 Hiroshi Okajima Hiv virus neutralizing antibody
FR2658197B1 (en) * 1990-02-14 1992-05-22 Inst Nat Sante Rech Med RESTRICTED MONOCLONAL ANTIBODIES RECOGNIZING A PEPTIDE ASSOCIATED WITH A MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN - APPLICATIONS TO DIAGNOSIS AND TREATMENT.
DE4029227A1 (en) * 1990-09-14 1992-03-19 Imtox Gmbh MEDICINAL PRODUCT CONTAINING CD14
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
WO1993019772A1 (en) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
AU674891B2 (en) * 1992-10-15 1997-01-16 Toray Industries, Inc. Process for producing major histocompatibility antigen class II protein and material having the same immobilized thereon
DE69434812D1 (en) * 1993-05-28 2006-09-14 Scripps Research Inst METHODS OF INHIBITION OF CD14-DEPENDENT CELL ACTIVATION
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
JPH10511652A (en) 1998-11-10
WO1996020215A2 (en) 1996-07-04
WO1996020215A3 (en) 1996-10-10
BR9510554A (en) 1999-06-29
CN1171117A (en) 1998-01-21
CA2208233A1 (en) 1996-07-04
CZ186897A3 (en) 1998-03-18
AU4347696A (en) 1996-07-19
HUT77468A (en) 1998-05-28
EP0800534A2 (en) 1997-10-15
SK80697A3 (en) 1997-12-10

Similar Documents

Publication Publication Date Title
ZA963287B (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
PL327312A1 (en) Tricyclic amides useful in inhibiting action of g protecin and in treatment of poliferation-type diseases
EP0963219A4 (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
HU9602583D0 (en) Gel for treatment of skin diseases and for disinfection of the skin
HUP9802662A3 (en) Substituted liposaccharides useful in the treatment and prevention of endotoxemia
FI950587A (en) Methods useful in the prevention and treatment of endotoxin poisoning
EP0924983A4 (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
PL320922A1 (en) Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
EP0719791A3 (en) Medicaments for the treatment of restenosis and arterial sclerosis
NO20001412D0 (en) Compositions and Methods in the Treatment of Respiratory Disorders
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
IL116142A0 (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
IL119459A0 (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
NO954175D0 (en) Use of vWF-containing concentrates as combination therapy in antithrombotic and fibrinolytic therapy
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
PL330797A1 (en) Derivatives of piperidinacetic acid and their application in treating thrombotic disorders
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
EP1009433A4 (en) Therapeutic composition and method of treatment
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
EP0893123A4 (en) Agent for use in the prevention and treatment of disorders associated with various types of ageing
EP0696055A3 (en) Electronic assemblies and methods of treatment
AU3705697A (en) Proendothelin and hemoglobin in the treatment of acute hemorrhage
GB9419906D0 (en) Bnezoic amide retinoids for use in the treatment of skin diseases and cancer
AUPM932194A0 (en) Encapsulated substances and their use in the treatment of animals
AU1554295A (en) Method for treatment and prevention of disease in animals